Abstract Library

#4587 Exploring the splicing landscape to identify survival-related biomarkers in small intestine neuroendocrine neoplasms

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) is challenging due to their rarity and complexity. While transcriptomic subtypes have been identified, the mechanisms behind their progression are still unclear. The process of RNA splicing is often altered in cancer, and our group has described that such dysregulation is also present in various NENs.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, García Vioque V, Pedraza-Arévalo S, Hernando Cubero J, García A,

Keywords: small intestine neuroendocrine tumour, splicing, biomarker, survival, ki-67, RNA,

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4431 Systemic treatment in metastatic pheochromocytomas and paragangliomas: Optimal moment for starting and outcomes of a multicentre Spanish cohort

Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs), collectively referred to as PPGLs, are relatively rare endocrine tumours with significant clinical variability and metastatic behaviour. Treatment strategies must be tailored individually due to the heterogeneity in their behaviour.

Conference:

Presenting Author: Del Olmo-García M

Authors: Hernández-Rienda L, Contreras-Saldarriaga J, Hernando Cubero J, García Alvarez A, Prado-Wohlwend S,

Keywords: Pheochromocytoma, paraganglioma, PPGL, metastatic, SSA, Radionuclide, chemotherapy,

#4417 Efficacy of immune checkpoint inhibitors (ICI) in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents

Introduction: Alkylating chemotherapy (ALK) is frequently used in patients with PanNETs. It may favour grade progression and acquisition of a hypermutator phenotype associated with frequent alterations of the MMR genes, suggesting a potential benefit of ICI.

Conference:

Presenting Author:

Authors: de Mestier L, Apostolidis L, Koumarianou A, Hernando Cubero J, Riechelmann R,

Keywords: immune checkpoint inhibitor, immunotherapy, hypermutagenicity, alkylating agents, tumour mutational burden, mismatch repair,

#4352 What can a reference centre offer to patients? Evolution of first visits for neuroendocrine and endocrine tumours and its relation to clinical trials availability.

Introduction: Endocrine and neuroendocrine neoplasia (NEN), which include gastroenteropancreatic neuroendocrine tumours, thyroid cancer and adrenal carcinoma, have a low incidence, making their diagnosis and treatment difficult. Due to this complexity, patients should be managed at specialised centres; however, the lack of official referral networks complicates the concentration of cases.

Conference:

Presenting Author: Martinez-Badal S

Authors: Martínez-Badal S, Hernando Cubero J, García Alvarez A, Elguero B, Alcantara A,

Keywords: Neuroendocrine, Clinical Trial, Reference Centre, Patient referral,